A5039557995- PARP inhibition in cancer therapy
- DNA Repair Mechanisms
- Acute Myeloid Leukemia Research
- Chromatin Remodeling and Cancer
- Migraine and Headache Studies
- Epigenetics and DNA Methylation
- CRISPR and Genetic Engineering
- Cancer Genomics and Diagnostics
- Histone Deacetylase Inhibitors Research
- Cancer-related molecular mechanisms research
- Telomeres, Telomerase, and Senescence
- Psychosomatic Disorders and Their Treatments
- Chronic Lymphocytic Leukemia Research
- Genomics and Chromatin Dynamics
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Trigeminal Neuralgia and Treatments
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Botulinum Toxin and Related Neurological Disorders
- Integrated Circuits and Semiconductor Failure Analysis
- Health Literacy and Information Accessibility
- Protein Degradation and Inhibitors
- Hemoglobinopathies and Related Disorders
- Fibroblast Growth Factor Research
- Genetic and Kidney Cyst Diseases
- Body Image and Dysmorphia Studies
Kanagawa Prefectural Hospital Organization
2023
Kanagawa University of Human Services
2023
Mayo Clinic
2023
Saitama International Medical Center
2021
Saitama Medical University
2021
Neuropsychiatric Research Institute
2021
Johns Hopkins University
2011-2019
Sidney Kimmel Comprehensive Cancer Center
2013-2019
Broad Institute
2017
Johns Hopkins Hospital
2016
Abstract Pancreatic carcinomas with acinar differentiation, including cell carcinoma, pancreatoblastoma and mixed are distinct pancreatic neoplasms poor prognosis. Although recent whole‐exome sequencing analyses have defined the somatic mutations that characterize other major of pancreas, molecular alterations underlying differentiation remain largely unknown. In current study, we sequenced exomes 23 surgically resected differentiation. These revealed a relatively large number genetic at...
Emerging evidence suggests that tumor cells metastasize by co-opting stem cell transcriptional networks, although the molecular underpinnings of this process are poorly understood. Here, we show for first time high mobility group A1 (HMGA1) gene drives metastatic progression in triple negative breast cancer (MDA-MB-231, Hs578T) reprogramming to a stem-like state. Silencing HMGA1 expression invasive, aggressive dramatically halts growth and results striking morphologic changes from...
Abstract Background Although the high mobility group A1 ( HMGA1 ) gene is widely overexpressed in diverse cancers and portends a poor prognosis some tumors, molecular mechanisms that mediate its role transformation have remained elusive. functions as potent oncogene cultured cells induces aggressive lymphoid tumors transgenic mice. Because chromatin remodeling proteins regulate transcription, thought to drive malignant by modulating expression of specific genes. Genome-wide studies define...
In preclinical studies, the PARP inhibitor veliparib enhanced antileukemic action of temozolomide through potentiation DNA damage. Accordingly, we conducted a phase 1 study with escalating doses in patients relapsed, refractory acute myeloid leukemia (AML) or AML arising from aggressive malignancies.
Abstract Background We had previously demonstrated overexpression of fibroblast growth factor receptor-4 (FGFR4) in hepatocellular carcinoma (HCC). However, additional molecular mechanisms resulting amplified FGFR4 signaling HCC remain under-studied. Here, we studied the mechanistic role its co-receptor klotho-beta (KLB) driving elevated activity progression. Results Quantitative real-time PCR analysis identified frequent elevation KLB gene expression tumors relative to matched non-tumor...
Many cancers comprise heterogeneous populations of cells at primary and metastatic sites throughout the body. The presence or emergence distinct subclones with drug-resistant genetic epigenetic phenotypes within these can greatly complicate therapeutic intervention. Liquid biopsies peripheral blood from cancer patients have been suggested as an ideal means sampling intratumor heterogeneity for diagnostics, monitoring guidance. However, current molecular diagnostic sequencing methods are not...
Many acute treatment options exist for migraine. However, large-scale, head-to-head comparisons of effectiveness from real-world patient experience reports are lacking.
DNA repair defects have been previously reported in myeloproliferative neoplasms (MPN). Inhibitors of PARP shown activity solid tumors with homologous recombination (HR). This study was performed to assess MPN sensitivity inhibitors ex vivoHR pathway integrity circulating myeloid cells evaluated by assessing the formation RAD51 foci after treatment ionizing radiation or inhibitors. Sensitivity erythroid and progenitors using colony assays.Six 14 primary samples had reduced exposure...
Abstract Objective To assess the real‐world effectiveness of ubrogepant by evaluating self‐reported satisfaction with pain relief, ability to think clearly, and return normal function in individuals who had used treat a migraine episode within preceding 14 days. Background Ubrogepant is an oral calcitonin gene–related peptide receptor antagonist approved for acute treatment adults. Few studies have evaluated ubrogepant. Methods The UNIVERSE study was observational, cross‐sectional survey...
// M. Zulfiquer Hossain 1 , Megan A. Healey Calvin Lee Weijie Poh Sashidhar R. Yerram Kalpesh Patel Nilofer S. Azad James G. Herman and Scott E. Kern Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School Medicine, Baltimore, Maryland Correspondence: Kern, email: Keywords : cancer, gene methylation, demethylation, DNA-intercalator, quinacrine, DNMT inhibitor, epigenetics, silencing re-activation expression, small molecule-DNA interactions Received...
Abstract Background The nature of COVID-19 pandemic measures has altered the clinical management migraine, and also created barriers to evaluate impact such migraine patients. Using Migraine Buddy smartphone application, we assessed on in users residing United States. Methods is a application by individuals record their headache episodes, characteristics, coping mechanisms. For this study, anonymized self-reported data from 163,176 adult States between January 2020 May 2020, were analyzed...
Although acute and preventive treatments for migraine are commonly given in combination, data on the real-world effectiveness of ubrogepant as an treatment when used with anti-calcitonin gene-related peptide (CGRP) monoclonal antibody (with or without onabotulinumtoxinA) limited. This analysis sought to evaluate effectiveness, satisfaction, optimization combination anti-CGRP antibody, concomitant onabotulinumtoxinA. prospective, multiple-attack, open-label, observational study (COURAGE)...
Defective homologous recombination (HR) has been reported in multiple myeloid disorders, suggesting a shared dysregulated pathway these diverse malignancies. Because targeting HR-defective cancers with PARP inhibition (PARPi) yielded clinical benefit, improved understanding of HR defects is needed to implement this treatment modality.We used an ex vivo irradiation-based assay evaluate repair, gene promoter methylation, and mRNA expression primary neoplastic cells. In vitro BRCA1 silencing...
<h3>Objective:</h3> To simultaneously compare patient-reported treatment effectiveness of 25 acute migraine medications using a big-data approach. <h3>Background:</h3> Many options exist for migraine. However, large-scale, head-to-head comparisons from real-world patient experience reports are lacking. <h3>Design/Methods:</h3> This is cross-sectional analysis 10,842,795 attack records extracted an e-diary smartphone application between June 30, 2014, and July 2, 2020. We analyzed among seven...
To examine real-world effectiveness of ubrogepant for the acute treatment migraine in patients who switched to due lack efficacy their prior treatment.
Abstract Despite advances in our ability to detect and treat breast cancer, it remains a leading cause of death women with cancer worldwide, the incidence is rising. Approximately 15-20% all cases are classified as triple negative (TNBC), subtype that frequently associated rapid progression poor outcome. TNBC refers lack detectable markers for estrogen receptor (ER), progesterone (PR), Her2/neu amplification. These tumors do not respond most effective least toxic therapies, including...